β1 integrin-mediated multicellular resistance in hepatocellular carcinoma through activation of the FAK/Akt pathway

Journal of International Medical Research

Volumn 46, Issue 4, 2018, Pages 1311-1325

  Tian, Tao ^a   Li, Chun Li ^a   Fu, Xiao ^a   Wang, Shu Hong ^a   Lu, Jun ^a   Guo, Hui ^a   Yao, Yu ^a   Nan, Ke Jun ^a   Yang, Yu Juan ^b  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

focal adhesion kinase; hepatocellular carcinoma; multicellular resistance; protein kinase B; 1 integrin

Indexed keywords

BETA1 INTEGRIN; CISPLATIN; FLUOROURACIL; FOCAL ADHESION KINASE; PROTEIN KINASE B; BENZAMIDE DERIVATIVE; DEFACTINIB; PYRAZINE DERIVATIVE; SULFONAMIDE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; DRUG EFFECT; DRUG RESISTANCE; LIVER TUMOR; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

APOPTOSIS; BENZAMIDES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; INTEGRIN BETA1; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; SULFONAMIDES;

EID: 85044821162     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060517740807     Document Type: Article

References (35)

1. Chen W, Zheng R, Baade PD. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115–132.
2. Yang N, Ekanem NR, Sakyi CA. Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics. Adv Drug Deliv Rev 2015; 81: 62–74.
3. Meli L, Jordan ET, Clark DS. Influence of a three-dimensional, microarray environment on human cell culture in drug screening systems. Biomaterials 2012; 33: 9087–9096.
4. Lovitt CJ, Shelper TB, and Avery VM., Evaluation of chemotherapeutics in a three-dimensional breast cancer model. J Cancer Res Clin Oncol 2015; 141: 951–959.
5. Takai A, Fako V, Dang H. Three-dimensional organotypic culture models of human hepatocellular carcinoma. Sci Rep 2016; 6: 21174.
6. Zhang F, Xu R, and Zhao MJ., QSG-7701 human hepatocytes form polarized acini in three-dimensional culture. J Cell Biochem 2010; 110: 1175–1186.
7. Lin RZ, Chou LF, Chien CC. Dynamic analysis of hepatoma spheroid formation: roles of E-cadherin and beta1-integrin. Cell Tissue Res 2006; 324: 411–422.
8. Chitcholtan K, Sykes PH, and Evans JJ., The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer. J Transl Med 2012; 10: 38–53.
9. Longati P, Jia X, Eimer J. 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer 2013; 13: 95–107.
10. Cui J, Guo YH, Zhang HY, Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids. Onco Targets Ther 2014; 7: 353–363.
11. Cui J, Nan KJ, Tian T. Chinese medicinal compound delisheng has satisfactory anti-tumor activity, and is associated with up-regulation of endostatin in human hepatocellular carcinoma cell line HepG2 in three-dimensional culture. World J Gastroenterol 2007; 13: 5432–5439.
12. Li CL, Tian T, Nan KJ. Survival advantages of multicellular spheroids vs. monolayers of HepG2 cells in vitro. Oncol Rep 2008; 20: 1465–1471.
13. Desoize B, and Jardillier J., Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 2000; 36: 193–207.
14. Naci D, Vuori K, and Aoudjit F., Alpha2beta1 integrin in cancer development and chemoresistance. Semin Cancer Biol 2015; 35: 145–153.
15. Iwamoto DV, and Calderwood DA., Regulation of integrin-mediated adhesions. Curr Opin Cell Biol 2015; 36: 41–47.
16. Desgrosellier JS, and Cheresh DA., Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9–22.
17. Lahlou H, and Muller WJ., β1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer. Breast Cancer Res 2011; 13: 229.
18. Zhao XK, Cheng Y, Liang Cheng M. Focal adhesion kinase regulates fibroblast migration via integrin beta-1 and plays a central role in fibrosis. Sci Rep 2016; 6: 19276.
19. Casar B, Rimann I, Kato H. In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated beta1 integrin and induction of FAK/PI3K/Akt motility signaling. Oncogene 2014; 33: 255–268.
20. Kanteti R, Batra SK, Lennon FE. FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget 2016; 7: 31586–31601.
21. Tai YL, Chen LC, and Shen TL., Emerging roles of focal adhesion kinase in cancer. Biomed Res Int 2015; 2015: 690690.
22. Torimura T, Ueno T, Kin M. Coordinated expression of integrin alpha6beta1 and laminin in hepatocellular carcinoma. Hum Pathol 1997; 28: 1131–1138.
23. Bogorad RL, Yin H, Zeigerer A. Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice. Nat Commun 2014; 5: 3869.
24. Speicher T, Siegenthaler B, Bogorad RL, Knockdown and knockout of β1-integrin in hepatocytes impairs liver regeneration through inhibition of growth factor signalling. Nat Commun 2014; 5: 3862.
25. Jiang X, Wang J, Zhang K. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells. Med Oncol 2015; 32: 141.
26. Eke I, Deuse Y, Hehlgans S, β₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest 2012; 122: 1529–1540.
27. Huang C, Park CC, Hilsenbeck SG. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res 2011; 13: R84.
28. Park CC, Zhang H, Pallavicini M. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 2016; 66: 1526–1535.
29. Eke I, and Cordes N., Focal adhesion signaling and therapy resistance in cancer. Semin Cancer Biol 2015; 31: 65–75.
30. Xu X, He Y, Miao X. Cell adhesion induces overexpression of chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) and contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells. Leuk Res 2016; 47: 54–62.
31. Wang J, Zhang X, Li X. Anti-gastric cancer activity in three-dimensional tumor spheroids of bufadienolides. Sci Rep 2016; 6: 24772.
32. Galateanu B, Hudita A, Negrei C. Impact of multicellular tumor spheroids as an in vivo-like tumor model on anticancer drug response. Int J Oncol 2016; 48: 2295–2302.
33. Liu LX, Jiang HC, Liu ZH. Integrin gene expression profiles of human hepatocellular carcinoma. World J Gastroenterol 2002; 8: 631–637.
34. Mundi PS, Sachdev J, McCourt C. AKT in cancer: new molecular insights and advances in drug development. Br J Clin Pharmacol 2016; 82: 943–956.
35. Polivka J, Jr and Janku F., Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 2014; 142: 164–175.